Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Approvals Action
Long wait over for blood cancer treatment
After securing US approval in 2009, blood cancer treatment Folotyn has arrvied in Australia; a new dose of Copaxone has also been registered but not by current sponsor bioCSL.
Trust deficit holding back Aussie pharma
Why, when it expects continuing increases in sales and profits, does Aussie pharma remain stuck in an ongoing cycle of negative sentiment?
Open Forum
Lipitor failure should give ACCC heartburn
The failure of its case against Pfizer is a blow for the ACCC. Not only did it fail to prove its allegations but Pfizer's successful contention that the watchdog made a basic legal mistake is embarrassing.
Pipeline Monitor
New filings from Roche, Pfizer
Roche's Genentech arm files a new combination treatment for melanoma and Pfizer puts forward Rapamune in rare lung disease.
Working Life
Five trends for pharma's working future
As global forces continue to impinge on pharma, they are changing the landscape of work. These five trends are what you need to know to understand how change will affect your career and workplace.